Turn this list into pipeline.
Biotech Companies in Bristol: 49 Active Firms (2026)
Biotech companies in Bristol develop biological therapeutics, diagnostics and research tools across the city's life-sciences cluster.
Demand tends to sit in a few buying centres: translational research teams, clinical-development groups, diagnostics procurement, and life-sciences R&D functions that need validated tools rather than generic consultancy. Sellers usually face specialist buyers in healthcare, pharmaceutical, academic and research-services settings, with sales cycles shaped by evidence generation, laboratory validation and procurement review. The fit is typically B2B, though end markets may sit close to public healthcare pathways where diagnostics or therapeutics are involved. Engagements are rarely light-touch: even smaller contracts tend to require scientific credibility, quality documentation and continuity of specialist staff before a customer will depend on the work.
Read more
Bristol has 49 biotech companies actively trading, a compact local cluster rather than a broad national-scale pool. Reported employment across the cohort totals 175 people, so the footprint is specialist and laboratory-led rather than labour-intensive. The profile fits a city cluster built around small scientific teams: some firms have moved beyond early trading, but the local base is still weighted towards businesses where regulatory work, research partnerships and product validation matter as much as sales capacity.
Regulatory exposure depends on the activity rather than the label. Bristol therapeutics and diagnostics firms that move towards clinical use sit within the UK life-sciences framework, with the MHRA setting standards, approving clinical trial applications, assessing marketing authorisations and monitoring safety after approval through pharmacovigilance. Clinical trials bring Good Clinical Practice, ethics review and informed-consent obligations. Market access can add another layer when approved medicines or diagnostics are assessed for routine public healthcare use by NICE. Trade bodies such as the ABPI and BioIndustry Association shape policy discussions, but they do not remove the need for product-level evidence.
Bristol’s biotech outlook appears tied to whether specialist teams can convert research capability into regulated products without losing momentum during validation and market-access work. The local cohort tends to look more early-commercial than mature, which may keep partnership and licensing routes central. Scarcity of scaled revenue businesses also points to selective consolidation, particularly where platform technologies, diagnostics capabilities or research tools overlap. Regulatory pressure is unlikely to ease; buyers will keep asking for reproducible evidence, quality systems and credible routes into clinical or laboratory use. That favours firms with disciplined product focus over broad scientific-services positioning.
49
Active firms
2026
2
Above £5M
reported revenue
15
New since 2022
incorporations
Key facts
About 4% of the trading cohort reports turnover above £5M (2 of 49 firms) — the rest sits below that revenue band.
30% of the cohort was incorporated since 2022 (15 firms), so a sizeable share is in its first few filing cycles.
MHRA oversight covers clinical trial applications, marketing authorisations and post-authorisation pharmacovigilance for UK biotech and biopharmaceutical activity.
Clinical trials must follow Good Clinical Practice, ethics review and informed-consent requirements.
The UK life-sciences industry generated £146.9 billion in turnover in 2023/2024, with biopharmaceutical activity accounting for £98.9 billion and 67% of the total.
UK biotech raised £3.5 billion in equity investment in 2024, up 94% on 2023, with financing concentrated in a small number of large rounds, mainly from USA investors.
The UK accounted for 11.5% of global medical-sciences citations in 2023, behind the USA and China.
Top Bristol biotech companies
Cellvoyant Technologies Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops AI-based software and services for analysing cell imaging data to support development of cell therapies. Provides a cloud platform that predicts cell states and outcomes from images, and…
Serves biotech and cell therapy R&D teams developing cell-based therapeutics, selling to scientists and process development teams that need predictive cell analytics and optimisation support for…
Financial Health
StableStable · Hiring · 87% CAGR over 3y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops, manufactures and supplies biochemical reagents, antibodies, proteins, dyes and related laboratory products used in life science research, including compounds for cell biology, pharmacology,…
Serves life science researchers and laboratory buyers in academic, biotech and pharmaceutical R&D organisations worldwide, especially scientists working in pharmacology, cell biology, neuroscience…
Financial Health
StrongStrong · Hiring · 13% CAGR over 4y
Location
Genomic Labs Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops in vitro diagnostic devices for rapid detection and identification of bacteria in blood samples. Technology analyses pathogens and antimicrobial resistance profiles to help clinicians select…
Serves hospitals, clinicians, microbiology teams and healthcare organisations involved in sepsis care and antimicrobial resistance management, with partnerships across the healthcare diagnostics…
Financial Health
StrongStrong · Growing, Hiring · 36% CAGR over 4y
Location
Scarlet Therapeutics Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops red blood cell‑based therapeutics using engineered cells that carry therapeutic proteins. Operates a biotechnology platform to produce therapeutic red blood cells from cell lines for…
Financial Health
StableStable
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops lipid nanoparticle (LNP) targeting technologies for drug delivery. Its NanoPilot platform engineers LNPs to deliver therapeutics to specific cell types while reducing off‑target liver…
Serves pharmaceutical and biotech companies developing LNP-based therapeutics, including teams seeking licensing opportunities for targeted drug-delivery technologies.
Financial Health
StableStable · -10% CAGR over 4y
Location
NEUROCHASE LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops drug delivery systems for the central nervous system, including convection‑enhanced delivery devices for gene and other therapeutics. Provides consultancy, protocol development, training,…
Serves biotech and pharmaceutical companies developing CNS therapies, as well as CROs and clinical trial teams involved in neurological disease programmes.
Financial Health
StableStable · -7% CAGR over 2y
Location
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
StrongStrong · Hiring · 108% CAGR over 3y
Location
RANVIER HEALTH LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops diagnostic tools and biomarkers for mental health and neurological conditions. Creates taste‑based screening tests, blood biomarker assays and computational models to detect, monitor and…
Serves patients seeking answers and clinicians managing depression, anxiety, Alzheimer’s and Parkinson’s, with relevance to healthcare organisations and investors in mental health and neurology…
Financial Health
WeakWeak · Hiring · 19% CAGR over 4y
Location
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsServes life sciences researchers and R&D teams in academic, biotechnology and pharmaceutical organisations.
Financial Health
DistressedDistressed
Location
PLASMIDSAURUS LTD
Trajectory
1y · 2025–NowProvides DNA and RNA sequencing services for research, including whole plasmid, amplicon, RNA‑seq, whole genome, AAV and microbiome sequencing. Accepts biological samples and returns analyzed…
Sells to scientific researchers and R&D teams needing sequencing services, including biotech startups, pharmaceutical companies, academic and research labs, and independent scientists or biohackers.
Financial Health
Insufficient historyInsufficient history
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and produces bio‑inspired peptide biomaterials designed to improve adhesion in challenging environments. Supplies engineered peptides for use in medical adhesives, industrial applications…
Serves B2B innovation partners and product developers in medical devices, wound and ostomy care, industrial adhesives, security/optics and personal care, especially firms integrating ingredients into…
Financial Health
WeakWeak · Hiring · 6% CAGR over 2y
Location
Folium Food Science Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops CRISPR-Cas biotechnology to control bacteria in animal microbiomes. Produces feed additives and biological tools that selectively eliminate pathogenic microbes while preserving beneficial…
Targets B2B customers in animal agriculture, especially poultry and livestock producers, feed ingredient companies and agrifood partners concerned with farmed animal health, food safety and…
Financial Health
DistressedDistressed · -14% CAGR over 3y
Location
Glimpse Technology Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StrongStrong · Hiring · 22% CAGR over 2y
Location
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsDevelops and manufactures hyaluronic acid‑based orthopedic products for regenerative medicine and osteoarthritis treatment, including viscosupplement injections, cartilage repair scaffolds, bone…
Serves orthopedic surgeons, sports medicine clinicians, hospitals and clinics treating osteoarthritis and soft-tissue or bone injuries, with patient-facing resources for people seeking care worldwide.
Financial Health
WeakWeak · -18% CAGR over 1y
Location
Innotive Diagnostics Limited
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops point‑of‑care diagnostic tests for urinary tract infections, providing on‑site detection of bacterial pathogens and antimicrobial susceptibility within about an hour. Focuses on research and…
Serves healthcare providers and clinical settings treating patients with uncomplicated UTIs, particularly point-of-care teams seeking rapid antimicrobial susceptibility results without relying on…
Financial Health
StrongStrong · Hiring · 64% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops rapid point‑of‑care diagnostic technologies for detecting infections and guiding antibiotic selection. Its platforms, including VERI-5 and SCFI, analyse patient samples to identify pathogens…
Serves doctors, clinicians and small-animal veterinary practices involved in infection management and antibiotic prescribing, with an emphasis on point-of-care settings and UTI care.
Financial Health
StableStable · Hiring · 3% CAGR over 4y
Location
Impulsonics Ltd
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops laboratory automation technology that uses acoustic waves to perform operations inside microplate wells, enabling manipulation of cells and biological samples and supporting automated…
Serves biotech and life science laboratories, scientists, and automation/product teams, including organisations looking to integrate acoustic lab technology into their own products.
Financial Health
DistressedDistressed · 0% CAGR over 1y
Location
FerryX Ltd
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy
Location
Revolver Therapeutics Limited
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
StableStable · 0% CAGR over 1y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · 0% CAGR over 4y
Location
VirTus Respiratory Research Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsProvides contract research services for respiratory drug development, including preclinical in vitro and in vivo studies, human viral challenge trials, and clinical trial management for…
Serves multinational pharmaceutical companies and small biotech enterprises developing respiratory medicines, vaccines, antivirals and immunomodulatory drugs, especially teams needing preclinical or…
Financial Health
StrongStrong · Growing, Hiring · 33% CAGR over 3y
Location
ALPHA ME LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed · 0% CAGR over 1y
Location
Vetneurotechnicks Ltd
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong
Location
Unlock all 49 leads
Showing 23 of 49 — +26 more with verified decision-maker contacts, live data, and CRM sync.
How Bristol biotech companies work and how to sell to them
What they do
Bristol biotech firms usually earn revenue from a mix of research contracts, licensing, staged development partnerships, diagnostics supply, research-tool sales and specialist services attached to biological product development. Many remain project-led, with commercial activity tied to validation work rather than repeat software-style usage. Pricing tends to follow the scientific risk: fixed-fee laboratory packages for defined assays, milestone-based terms for therapeutics and platform work, and negotiated licences where intellectual property is central. Engagements often include quality documentation, technical transfer and ongoing support, because a buyer is not just purchasing an output; it is taking a dependency on evidence that may later sit inside a regulated development pathway.
Who they sell to
Most sell to life-sciences R&D teams, pharmaceutical and biotechnology groups, healthcare-facing diagnostics buyers, universities and research-services organisations. The usual stakeholders are scientific founders, translational research leads, clinical-development heads, procurement teams, quality managers and, when budgets are material, finance directors. Sales cycles tend to be measured in months, because buyers want protocol detail, validation history, evidence of repeatability and assurance that specialist staff will stay involved. Smaller research-tool purchases may be handled directly by laboratory teams, while diagnostics, clinical-development and public healthcare-adjacent work can move through procurement review, technical panels or tender-style processes.
What they buy
Most Bristol biotech firms tend to spend on the operating layer around science: laboratory equipment and consumables, outsourced assay or manufacturing support, secure data storage, quality-management systems, document control, sample tracking, regulatory affairs advice and specialist legal work around intellectual property. Commercial teams may also need CRM, partnership pipeline management, bid support and marketing aimed at technical audiences rather than broad demand generation. As teams move from research into validation, hiring often shifts towards quality, regulatory, clinical operations and business development. Sellers with finance, HR or accounting propositions usually need to map the pitch to grants, R&D costs, project accounting and audit readiness rather than generic small-business administration.
Why and how to sell to them
Biotech buyers tend to evaluate suppliers when a project moves from exploratory research into repeatable validation, when a regulated study is being prepared, or when a partnership discussion creates pressure to tidy evidence, documentation and delivery processes. Other triggers include senior scientific hires, new commercial leadership, expansion of laboratory work, or a move towards diagnostics and therapeutics pathways where MHRA expectations may apply. Outbound works better when it names a specific operational risk: loss of experimental traceability, slow procurement packs, fragmented quality records, scarce regulatory capacity or avoidable delays in partner due diligence. Generic productivity claims usually land poorly with scientific teams.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Bristol
Related directories
Frequently asked questions
How many biotech companies are there in the Bristol?↓
What counts as a biotech company in this list?↓
Which are the largest biotech companies in the Bristol?↓
What do biotech companies in the Bristol actually do?↓
How does Bristol biotech compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical biotech companies in the Bristol?↓
Are these mostly new or established biotech companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 49 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.